Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 2262 • 2016 ACR/ARHP Annual Meeting
CR6086 a New Potent EP4 Receptor Antagonist with Immunomodulatory Activities
Tiziana Piepoli¹, Daniele Maggioni², Silvia Zerbi¹, Anna Stucchi¹, Laura Mennuni¹, Marco Lanza¹, Gianfranco Caselli¹ and Lucio Claudio Rovati¹, ¹Rottapharm Biotech, Monza, Italy, ²School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
Background/Purpose: In the early phase of rheumatoid arthritis (RA), PGE2 recruits different immune cells from the blood stream into target tissues. Via the EP4 receptor,…
Abstract Number: 595 • 2016 ACR/ARHP Annual Meeting
Cinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol
Vivian P. Bykerk¹, Paul Emery², Michael Weinblatt³, Gerd-Rüdiger Burmester⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Ronald van Vollenhoven⁷, Oana Purcaru⁸, Pauline Ralston⁹ and Clifton Bingham III¹⁰, ¹Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ²University of Leeds, Midlothian, United Kingdom, ³Brigham and Women’s Hospital, Boston, MA, ⁴Charité – University Medicine Berlin, Berlin, Germany, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁸UCB Pharma, Slough, United Kingdom, ⁹Hays Pharma, London, United Kingdom, ¹⁰Johns Hopkins University, Baltimore, MD
Background/Purpose: Rheumatoid arthritis (RA) is associated with work disability, loss of productivity and reduced quality of life. In established and early RA, compared with MTX…
Abstract Number: 2480 • 2016 ACR/ARHP Annual Meeting
Dose-Related Short Term Clinical Response to Initial Treatment with Methotrexate in Mono- and Combination Therapy in Early Rheumatoid Arthritis Patients – a Meta-Regression Analysis
SA Bergstra¹, CF Allaart¹, T Stijnen² and RBM Landewé^3,4, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Medical Statistics, LUMC, Leiden, Netherlands, Leiden, Netherlands, ³Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands, ⁴Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands
Background/Purpose: Recently, there has been a trend to start methotrexate (MTX) in higher doses, either as monotherapy or in combination with other drugs in rheumatoid…
Abstract Number: 608 • 2016 ACR/ARHP Annual Meeting
Initial Intensive Therapy of Adalimumab and Methotrexate Is Associated with Long-Term Structural Remission and Low Disease Activity after Adalimumab Discontinuation Is Maintained up to 3 Years in Japanese Patients: Hopeful-3 Study
Yoshiya Tanaka¹, Hisashi Yamanaka², Naoki Ishiguro³, Nobuyuki Miyasaka⁴, Katsuyoshi Kawana⁵, Naoki Agata⁵ and Tsutomu Takeuchi⁶, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Japan, ⁴Tokyo Medical and Dental University, Tokyo, Japan, ⁵Abbvie GK, Tokyo, Japan, ⁶Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Methods: Of 172 patients enrolled, 135 (ADA continuation, n=61; ADA discontinuation, n=74) with DAS28–CRP at both week 52 (start of HOPEFUL-2) and week 208…
Abstract Number: 2498 • 2016 ACR/ARHP Annual Meeting
Tender Joints Is a Consistent Negative Predictor of Sustained Remission in Aggressively Treated Patients with Early Rheumatoid Arthritis
Nina P. Sundlisater¹, Siri Lillegraven¹, Inge C Olsen¹, Anna-Birgitte Aga¹, Hilde B. Hammer², Till Uhlig¹, Desiree van der Heijde^1,3, Tore K Kvien¹ and Espen A. Haavardsholm¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumtology, Diakonhjemmet Hospital, Oslo, Norway, ³Dept of Rheumatology, Leiden University Medical Ctr, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) care has moved towards early diagnosis and treatment to improve long-term patient outcomes. Our objective was to assess prognostic factors for…
Abstract Number: 952 • 2016 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Evaluating Treatment Strategies (Continuation Versus Withdrawal) for Maintaining Low Disease Activity after 1 Year of Certolizumab Pegol in DMARD-Naive Patients with Early and Progressive, Active RA
Michael Weinblatt¹, Clifton Bingham III², Gerd-Rüdiger Burmester³, Vivian P. Bykerk⁴, Daniel E. Furst⁵, Xavier Mariette⁶, Désirée van der Heijde⁷, Ronald van Vollenhoven⁸, Brenda VanLunen⁹, Cécile Ecoffet¹⁰, Christopher Cioffi⁹ and Paul Emery¹¹, ¹Brigham and Women's Hospital, Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Charité – University Medicine Berlin, Berlin, Germany, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Université Paris-Sud, Paris, France, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁹UCB Pharma, Raleigh, NC, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹University of Leeds, Leeds, United Kingdom
Background/Purpose: There is interest in tapering or stopping biologic DMARD therapy in RA patients (pts) who have achieved sustained disease control.1 We report the results…
Abstract Number: 2525 • 2016 ACR/ARHP Annual Meeting
Patient Characteristics Predicting Remission Using Intensive Treatment Strategies in Early Rheumatoid Arthritis
Diederik Decock¹, Rene Westhovens^1,2, Veerle Stouten¹, Kristien Van der Elst^2,3, Johan Joly², Patrick Verschueren^1,2 and CareRA study group, ¹KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, ²Rheumatology, University Hospitals Leuven, Leuven, Belgium, ³KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium
Background/Purpose: Guidelines recommend to treat newly diagnosed Early Rheumatoid Arthritis (ERA) with intensive treatment strategies using Methotrexate (MTX) or a combination of csDMARDs and a…
Abstract Number: 956 • 2016 ACR/ARHP Annual Meeting
The Effect of Treatment Adjustments Aimed at DAS Remission on Physical Functioning in Undifferentiated and Rheumatoid Arthritis Patients in Low Disease Activity
SA Bergstra¹, OM Olivas Vergara¹, G Akdemir¹, GM Steup-Beekman², HK Ronday³, JB Harbers⁴, RBM Landewé^5,6 and CF Allaart¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Bronovo Hospital, The Hague, Netherlands, The Hague, Netherlands, ³Department of Rheumatology, HAGA hospital, The Hague, Netherlands, The Hague, Netherlands, ⁴Department of Rheumatology, Franciscus Hospital, Roosendaal, Netherlands, Roosendaal, Netherlands, ⁵Amsterdam Medical Center, Amsterdam, Netherlands, ⁶Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands
Background/Purpose: Should we aim at remission if patients are in low disease activity (LDA)? We assessed if rheumatoid or undifferentiated arthritis (RA, UA) patients who…
Abstract Number: 2536 • 2016 ACR/ARHP Annual Meeting
The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis
Rok Jese¹, Ales Ambrozic², Natasa Gaspersic², Alojzija Hocevar¹, Boris Lestan¹, Milena Pavic Nikolic¹, Martina Plešivčnik Novljan², Sonja Praprotnik³, Ziga Rotar¹, Alenka Šipek Dolničar¹, Dasa Suput Skvarca¹ and Matija Tomsic¹, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²Department of Rheumatology, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Slovenia, Ljubljana, Slovenia
Background/Purpose: In early rheumatoid arthritis (RA), first assessment by a rheumatologist and/or initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset are…
Abstract Number: 1095 • 2016 ACR/ARHP Annual Meeting
Periarticular Bone Loss in Arthritis Is Induced By Autoantibodies Against Citrullinated Vimentin
Cecilia Engdahl¹, Holger Bang², Katharina Dietel¹, Stefanie C Lang¹, Ulrike Harre¹ and Georg Schett³, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany, ²Orgentec Diagnostics, Mainz, Germany, ³Department of Internal Medicine III, Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nuremberg (FAU), Erlangen, Germany
Background/Purpose: Periarticular bone loss is a long known and early but yet insufficiently understood phenomenon in patients with rheumatoid arthritis. This study investigated whether autoimmunity…
Abstract Number: 2545 • 2016 ACR/ARHP Annual Meeting
Physicians, but Not Patients, Agree That EULAR Good Response Indicates Remission after 12 Weeks Treatment of Early Rheumatoid Arthritis
Samina A. Turk¹, Dirkjan van Schaardenburg^1,2, Linda A. Rasch³, Véronique Lugt¹, Willem F. Lems^1,3, Mike T. Nurmohamed^1,4 and Lilian van Tuyl³, ¹Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, Amsterdam Rheumatology and immunology Center, location Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ³Rheumatology, Amsterdam Rheumatology and immunology Center, location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, ⁴Rheumatology, Amsterdam Rheumatology and immunology Center, Location VU University Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: The Disease Activity Score (DAS) and the European League Against Rheumatism (EULAR) response criteria are commonly used to describe disease activity in Rheumatoid Arthritis…
Abstract Number: 12 • 2016 ACR/ARHP Annual Meeting
Benefit of Early Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid Arthritis and Undifferentiated Early Arthritis (CONAART)
Soledad Retamozo¹, Maria Jezabel Haye Salinas², Juan Pablo Pirola³, Diego Baenas², Ana C. Alvarez⁴, Veronica Saurit³, Alejandro Alvarellos⁵, Christian A. Waimann⁶, Gustavo Citera^7,8, Fernando Dal Pra⁹, Celeste Orozco⁹, Federico Ceccato¹⁰, Sergio Paira¹⁰, MV Martire¹¹, G Crespo Amaya¹¹, Anastasia Secco¹¹, M Mamani¹¹, Javier Rosa¹², Enrique Soriano¹², Josefina Marcos¹³, Mercedes Argentina García¹⁴, Carolina Costi¹⁵, María M Zalazar¹⁶, Alejandro Martinez Muñoz¹⁶, Oscar Luis Rillo¹⁷, Horacio Berman¹⁸, Alberto Berman¹⁸, Francisco Colombres¹⁸, Edson Javier Velozo¹⁹, Vicente Ricardo Juarez²⁰, M Crespo²⁰, A Quinteros²¹, M Leal²¹, G Salvatierra²², Monica Sacnún²³, R Quintana²³, M Abdala²⁴ and Francisco Caeiro²⁵, ¹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ²Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ³Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ⁴Hospital Privado Centro Medico de Cordoba, Cordoba, Argentina, ⁵Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ⁶Escuela Superior de Ciencias de la Salud, UNICEN., Olavarria,, Argentina, ⁷Rheumatology, Instituto de Rehabilitacion Psicofisica - Fundacion Reumatologica Argentina Dr. Osvaldo Garcia-Morteo, Buenos Aires, Argentina, ⁸Rheumatology, CONAART - IREP, Buenos Aires, Argentina, ⁹Instituto De Rehabilitación Psicofísica, Argentina, CABA, Argentina, ¹⁰Hospital Dr José María Cullen, Santa Fe, Argentina, ¹¹Hospital Bernardino Rivadavia, CABA, Argentina, ¹²Hospital Italiano De Buenos Aires, CABA, Argentina, ¹³Hospital San Martin, La Plata, Argentina, ¹⁴Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ¹⁵Hospital San Martín, LaPlata, Argentina, ¹⁶Hospital Pirovano, CABA, Argentina, ¹⁷Rheumatology Department, Hospital General de Agudos “Dr. Ignacio Pirovano”, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁸Centro Médico Privado De Reumatología (Tucumán), Tucumán, Argentina, ¹⁹Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, ²⁰Hospital Señor Del Milagro, Salta, Argentina, ²¹Centro Integral De Reumatología, Tucumán, Argentina, ²²Instituto Provincial De Rehabilitación Integral, Santiago del Estero, Argentina, ²³Hospital Provincial De Rosario, Rosario, Argentina, ²⁴Hospital Provincial Del Centenario, Rosario, Argentina, ²⁵Rheumatology, Hospital Privado Centro Medico De Córdoba, Cordoba, Argentina
Background/Purpose: To analyze clinical remission in patients with early RA and undifferentiated arthritis (UA) during the first 2 years of treatment using methotrexate (MTX) and…
Abstract Number: 1198 • 2016 ACR/ARHP Annual Meeting
Gene Enrichment Analysis Identifies Active CD40-CD40L Signaling in Early and Established Rheumatoid Arthritis
Yanxia Guo¹, Alice Walsh¹, Ursula Fearon², Malcolm D. Smith³, Mihir D Wechalekar⁴, Xuefeng Yin¹, Suzanne Cole¹, Carl Orr⁵, Trudy McGarry⁵, Mary Canavan⁵, Stephan Kelly⁶, Costantino Pitzalis⁷, Tai-An Lin¹, Xuejun Liu¹, Susanna Proudman⁸, Douglas J. Veale⁹ and Sunil Nagpal¹, ¹Immunology, Janssen Research & Development, Spring House, PA, ²St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ³Flinders University, Adelaide, Australia, ⁴Royal Adelaide Hospital, Adelaide, Australia, ⁵St. Vincent's University Hospital, Dublin, Ireland, ⁶Queen Mary University of London, London, United Kingdom, ⁷Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁸University of Adelaide, Adelaide, Australia, ⁹Consultant Rheumatologist, Centre for Arthritis and Rheumatic Disease, St. Vincent’s University Hospital and University College Dublin, Dublin 4, Ireland
Background/Purpose: CD40 and CD40L (CD154) are tumor necrosis factor (TNF) family members involved in the pathogenesis of various autoimmune diseases. While this pathway is active…
Abstract Number: 2645 • 2016 ACR/ARHP Annual Meeting
Treatments for Early Rheumatoid Arthritis (RA): A Systematic Review of Randomized Controlled Trials
Salvador R. Garcia¹, Maria A. Lopez-Olivo² and Maria Suarez-Almazor³, ¹Department of Medicine. Section of Allergy Immunology and Rheumatology., Department of Medicine, Section of Allergy Immunology and Rheumatology, Baylor College of Medicine, Houston, Texas, USA., Houston, TX, ²Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine,The University of Texas MD Anderson Cancer Center, Houston, Texas, USA,, Houston, TX, ³Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Houston, TX
Background/Purpose: The objective of this systematic review was to evaluate the clinical evidence on the efficacy of different drug regimens for the treatment of early…
Abstract Number: 115 • 2016 ACR/ARHP Annual Meeting
Early Inflammatory Arthritis Presentation, Management and Outcomes in Canadian Aboriginal Patients
Sujay Nagaraj¹, Cheryl Barnabe², Orit Schieir³, Vivian P. Bykerk⁴, Janet Pope⁵, Shahin Jamal⁶, Gilles Boire⁷, Edward Keystone⁸, Diane Tin⁹, Boulos Haraoui¹⁰, J Carter Thorne¹¹, Carol Hitchon¹² and Canadian Early Arthritis Cohort (CATCH) Investigators, ¹McCaig Institute for Bone and Joint Health, University of Calgary, Calgary, AB, Canada, ²Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ³Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, ⁴Divison of Rheumatology, Hospital for Special Surgery, New York, NY, ⁵University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁶University of British Columbia, Vancouver, BC, Canada, ⁷Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, ⁸Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Institute de Rheumatologie, Montreal, QC, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Differences in access to care that influence the timing and quality of treatment interventions may create outcome inequities for Aboriginal patients with inflammatory arthritis.…

« Previous Page
1
…
6
7
8
9
10
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].